NBIX

#760
Neurocrine Biosciences Inc
130.8100 USD
+3.55%
Sector: Atención Sanitaria
Básica: USD
Divisa de beneficio: USD
Rango diario
130.8100
130.8100
Rango anual
122.1375
160.1800
Cambio diario
+3.55%
Variación mensual
+0.31%
Variación en los últimos 6 meses
-9.79%
Cambio anual
-9.79%
Cierres anteriores
126.3200
Abrir
130.8100
Bid
Ask
Mínimo
130.8100
High
130.8100
Volumen
127
Ver el calendario completo

Financials

Visión general Informes Estadísticas
Trimestre Año
Informe de resultados Saldo Flujo de caja
Valor 202020212022202320242025 TTM

Neurocrine Biosciences Inc

Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992. It is headquartered in San Diego, California, and led by CEO Kyle Gano as of October 11, 2024. Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. In 2017, the company's drug valbenazine was approved in the US to treat adults with tardive dyskinesia. The company is also developing treatments that are in various stages of clinical research for Parkinson's disease, Tourette syndrome, and congenital adrenal hyperplasia and with a partner for endometriosis and uterine fibroids.

Noticias